Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096616 | 0.88 | KDM1A (0.36) | S1PR5BCHEHTR6KDM1AJAK2 | |
| SCHEMBL6099163 | 0.87 | MCL1 (0.43) | HTR7S1PR5BCL2BCL2L1MCL1 | |
| SCHEMBL6096133 | 0.87 | P2RX3 (0.41) | SSTR4JAK2JAK3PTK2ESR2 | |
| SCHEMBL6096847 | 0.85 | ALDH1A1 (0.44) | JAK2JAK3PTK2 | |
| SCHEMBL6098655 | 0.84 | MCL1 (0.41) | MCL1JAK2JAK3PTK2ESR2 | |
| SCHEMBL6098270 | 0.82 | ESR2 (0.44) | JAK2JAK3PTK2ESR2 | |
| SCHEMBL6474790 | 0.77 | HDAC1 (0.49) | HTR7SSTR4ABHD6BCHEHTR6 | |
| SCHEMBL6098488 | 0.77 | S1PR5 (0.37) | HTR7SSTR4S1PR5ABHD6BCL2 | |
| SCHEMBL6096642 | 0.76 | HRH3 (0.46) | HTR7HTR6BCL2BCL2L1MCL1 | |
| SCHEMBL6099152 | 0.75 | ALDH1A1 (0.47) | JAK2JAK3PTK2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022694-B2 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1406902-B1 | HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1406902-A1 | HEXAHYDROAZEPINO(4,5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003006466-A1 | HEXAHYDROAZEPINO (4, 5-G) INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | TPH1, HTR5A, TPH2 | HTR7 7/4885SSTR4 128/4885S1PR5 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.